 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...5556575859606162636465...858859» |
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia (clinicaltrials.gov) - Jun 14, 2024
P2, N=15, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- | Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Metastases: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib (clinicaltrials.gov) - Jun 13, 2024
P2, N=25, Suspended, Sponsor: Wake Forest University Health Sciences
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Aug 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> May 2025
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders (clinicaltrials.gov) - Jun 13, 2024
P=N/A, N=10, Completed, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> May 2025 Active, not recruiting --> Completed
- | Parsabiv (etelcalcetide) / Amgen
Preclinical, Journal: Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease. (Pubmed Central) - Jun 13, 2024
Further, Etel treatment prevented CKD-SHPT-induced deterioration in bone strength and mechanical behavior. Based on these findings, we conclude that in CKD-SHPT rats, Etel has multiscale beneficial effects in a bone that involve remodeling suppression, mineralization gene upregulation, and preservation of osteocytes.
- || Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: A Review of Novel Medical Treatments for Thyroid Eye Disease. (Pubmed Central) - Jun 13, 2024
Recently, several clinical trials are underway to assess the efficacy and safety of novel drugs targeting mTORC1, IL-6, FcRN, and IGF-1R in treating TED. With the explosive increase in interest from academia and pharmaceutical companies in TED, there is anticipation for the development of drugs that are equivalent or superior to teprotumumab while being safer.
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results from the GALACTIC-HF study. (Pubmed Central) - Jun 13, 2024
P3
In a cohort of patients with HFrEF, baseline cTnI concentrations were strongly associated with adverse clinical outcomes. Although cTnI concentrations were higher in patients treated with omecamtiv mecarbil, we did not find a differential effect of omecamtiv mecarbil on either safety or efficacy based on baseline cTnI status or change in cTnI.
- | Prolia (denosumab) / Amgen
Journal: Reshrinkage of Giant-Cell Tumor of the Bone in the Thoracic Vertebrae after Resumption of Denosumab Treatment: A Case Report. (Pubmed Central) - Jun 13, 2024
Although cTnI concentrations were higher in patients treated with omecamtiv mecarbil, we did not find a differential effect of omecamtiv mecarbil on either safety or efficacy based on baseline cTnI status or change in cTnI. No abstract available
- | Prolia (denosumab) / Amgen
Journal: Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type. (Pubmed Central) - Jun 13, 2024
In multivariate analysis, non-odontogenic MRONJ was significantly more common in patients with no osteolysis and with periosteal reaction. Conclusion Non-odontogenic MRONJ tends to occur more frequently in patients treated with high-dose DMB, and there were significantly more cases of non-osteolytic MRONJ without radiographic evidence of osteolysis or with periosteal reactions.
- Procysbi (cysteamine bitartrate delayed release) / Amgen
PATIENT REPORTED EXPERIENCES COMPARING IMMEDIATE RELEASE AND DELAYED RELEASE CYSTEAMINE (Lime room | Level -1) - Jun 13, 2024 - Abstract #SSIEM2024SSIEM_163;
Switching to DR cysteamine was positive for the majority of patients, therapy adherence improved and the burden of treatment decreased. Side effects were reported less frequently.
- | Tyvyt (sintilimab) / Eli Lilly, Stivarga (regorafenib) / Bayer
New trial, Combination therapy, Metastases: Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC (clinicaltrials.gov) - Jun 13, 2024
P=N/A, N=40, Not yet recruiting, Sponsor: The First People's Hospital of Changzhou
- | New trial: TARGET: Taiwan Severe Asthma Biologic Registry (clinicaltrials.gov) - Jun 12, 2024
P=N/A, N=500, Recruiting, Sponsor: Taichung Veterans General Hospital
- ||| carfilzomib / Generic mfg.
Trial suspension: CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov) - Jun 12, 2024
P1, N=18, Suspended, Sponsor: Hackensack Meridian Health
Side effects were reported less frequently. Recruiting --> Suspended
- Repatha (evolocumab) / Amgen, Astellas
Rethinking Prevention: Need for earlier intervention in Familial Hypercholesteremia despite Statin and PCSK9 Inhibitor Therapy (Kiosk 14) - Jun 12, 2024 - Abstract #NLA2024NLA_234;
Findings from the FOURIER trial revealed that evolocumab only reduced MACE by 15%, indicating a residual risk. Additionally, a 2024 study by Bj
- Repatha (evolocumab) / Amgen, Astellas
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus. (Kiosk 9) - Jun 12, 2024 - Abstract #NLA2024NLA_227;
Several smaller studies have suggested MCS is caused by either of the two major mechanisms: (1) some combination of minor genetic polymorphisms, or (2) presence of a single genetic mutation in one of the five genes regulating triglyceride metabolism including LPL, APOC2, APOA5, GPHIBP1, and LMF1. We postulate acceleration of ASCVD in our patient with MCS was multifactorial, including deposition of atherogenic triglyceride rich lipoproteins within blood vessels, in addition to the independent risk factor of elevated Lp(a).
- The Role of Structured Inpatient Lipid Protocols in Optimizing Non-Statin Lipid Lowering Therapy: A Review and Single-Center Experience () - Jun 12, 2024 - Abstract #NLA2024NLA_206;
The 2022 ACC ECDP on the role of nonstatin therapies for LDL-C lowering recommends aggressive combination therapy to lower LDL-C in very-high-risk patients. To effectively manage very-high-risk patients and ensure that they receive appropriate lipid-lowering therapy, it may be necessary to implement a structured inpatient protocol involving a multi-disciplinary approach in both the inpatient and outpatient setting.
- Leqvio (inclisiran) / Novartis
Treatment Patterns Among Early Inclisiran vs Anti (Kiosk 28) - Jun 12, 2024 - Abstract #NLA2024NLA_205;
Inclisiran had significantly higher adherence and lower rates of discontinuation vs. anti-PCSK9 mAbs at 12-month after initiation. Convenient dosing of inclisiran may be an option for patients who requires additional LDL-C lowering.
- Repatha (evolocumab) / Amgen, Astellas
Pericardial and Pleural Effusions after Evolocumab in a Patient with Severe Familial Hypercholesterolemia (Kiosk 2) - Jun 12, 2024 - Abstract #NLA2024NLA_191;
Delayed pleural and pericardial effusions after evolocumab in this patient with severe FH, supports the need for pre-treatment testing and discussion of alternatives. The severity of this uncommon response suggests a need for epidemiological studies.
- Cholib (fenofibrate/simvastatin) / AbbVie, Repatha (evolocumab) / Amgen, Astellas
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk (Kiosk 22) - Jun 12, 2024 - Abstract #NLA2024NLA_182;
It is important to note however, that at elevated triglyceride levels usually exceeding 300 mg/dL, calculated LDL levels are grossly inaccurate, and will not serve as a reliable marker of atherosclerotic cardiovascular disease (ASCVD) risk. Sniderman et al.
- || ivabradine / Generic mfg.
Clinical, Journal: Effect of ivabradine on structural and functional changes of myocardium and NT-proBNP levels in patients with stable coronary heart disease after coronary stenting. (Pubmed Central) - Jun 12, 2024
Therefore, the use of ivabradine along with standard therapy was appropriate for such a contingent of patients. The management of patients with stable coronary heart disease should combine adequate (surgical and pharmacological) treatment of the underlying disease, further individual medication correction of symptoms and circulatory disorders inherent in coronary heart disease and heart failure.
- | Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis
Journal: Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population. (Pubmed Central) - Jun 12, 2024
Incorporation of secukinumab and ustekinumab was economically feasible. These drugs are options for those who do not respond to or have contraindications to etanercept.
- |||| Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Real-world evidence: An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions (clinicaltrials.gov) - Jun 12, 2024
P=N/A, N=818, Active, not recruiting, Sponsor: Bayer
These drugs are options for those who do not respond to or have contraindications to etanercept. Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- | Kaitanni (cadonilimab) / Akesobio, Stivarga (regorafenib) / Bayer
New P2 trial: Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM (clinicaltrials.gov) - Jun 12, 2024
P2, N=44, Not yet recruiting, Sponsor: Jin-hong Chen
- | Venclexta (venetoclax) / Roche, AbbVie, Stivarga (regorafenib) / Bayer
New P1 trial, Combination therapy: Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 12, 2024
P1, N=20, Not yet recruiting, Sponsor: City of Hope Medical Center
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial: TPAP: Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres (clinicaltrials.gov) - Jun 11, 2024
P=N/A, N=200, Recruiting, Sponsor: AstraZeneca
- | Stivarga (regorafenib) / Bayer
Journal, HEOR, Real-world evidence, Real-world, Metastases: Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence. (Pubmed Central) - Jun 11, 2024
P=N/A, P3
Efficacy and safety in the Spanish cohorts reflected findings from the global cohorts, with evidence of a flexible dosing approach being adopted in routine clinical practice. Regorafenib use in patients with mCRC has evolved in the real-world setting, emphasizing the need for further research evaluating dosing patterns that can optimize clinical outcomes in these patients.Clinical trial registration: The CORRECT trial is registered at ClinicalTrials.gov, number NCT01103323; the CONSIGN trial is registered at ClinicalTrials.gov, number NCT01538680; the CORRELATE study is registered at ClinicalTrials.gov, number NCT02042144.
- | bemarituzumab (AMG 552) / Amgen
Journal, Metastases: Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. (Pubmed Central) - Jun 11, 2024
P2
Regorafenib use in patients with mCRC has evolved in the real-world setting, emphasizing the need for further research evaluating dosing patterns that can optimize clinical outcomes in these patients.Clinical trial registration: The CORRECT trial is registered at ClinicalTrials.gov, number NCT01103323; the CONSIGN trial is registered at ClinicalTrials.gov, number NCT01538680; the CORRELATE study is registered at ClinicalTrials.gov, number NCT02042144. In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, IO biomarker, Metastases: The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer. (Pubmed Central) - Jun 11, 2024
NGS analysis revealed that GNAS and KRAS alterations were associated with a worse treatment response and prolonged survival, respectively. In conclusion, a moderate-dose salvage lenvatinib-based regimen demonstrated promising clinical activity and tolerability in treating refractory mCRC.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, Clinical, Journal: Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab. (Pubmed Central) - Jun 11, 2024
P4
Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952).
- |||| rocatinlimab (KHK4083) / Amgen
Enrollment open: A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma (clinicaltrials.gov) - Jun 11, 2024
P2, N=428, Recruiting, Sponsor: Amgen
It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952). Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Journal: EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. (Pubmed Central) - Jun 10, 2024
Likewise, patient-derived organoids (PDOs) from individuals with ER+ mBC, progressing on palbociclib, exhibited up-regulation of EGFR and HER2 pathways. In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET+CDK4/6i in selected patients with ER+ mBC.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Correction to: Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease: Using a Genetic Risk Score. (Pubmed Central) - Jun 10, 2024
In conclusion, our findings suggest that inhibiting EGFR and HER2 pathways might overcome resistance to ET+CDK4/6i in selected patients with ER+ mBC. No abstract available
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal, HEOR, Real-world evidence, Real-world: Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia. (Pubmed Central) - Jun 10, 2024
Grade???3 adverse events were observed in 12.5% patients. Blinatumomab was found to be effective with a tolerable safety profile in real world setting.
- | Stivarga (regorafenib) / Bayer
Journal: Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients. (Pubmed Central) - Jun 10, 2024
Administering a low dose of regorafenib to patients with ALBI grade 2 reduces the RDI of regorafenib and lowers treatment efficacy, as an appropriate C0 of regorafenib is not maintained. Monitoring the C0 of regorafenib regularly is necessary to guide dose adjustment.
- | Granocyte (lenograstim) / Roche, Neulasta (pegfilgrastim) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan. (Pubmed Central) - Jun 10, 2024
Monitoring the C0 of regorafenib regularly is necessary to guide dose adjustment. Our study suggests that primary prophylaxis with either short- or long-acting G-CSF could be considered cost-effective for FN prevention in breast cancer patients receiving high-risk regimens.
- || Prolia (denosumab) / Amgen
Review, Journal: Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting. (Pubmed Central) - Jun 10, 2024
Our study suggests that primary prophylaxis with either short- or long-acting G-CSF could be considered cost-effective for FN prevention in breast cancer patients receiving high-risk regimens. Denosumab emerges as a potentially safe and effective option for enhancing bone health in CKD patients.
- || Stivarga (regorafenib) / Bayer
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer. (Pubmed Central) - Jun 10, 2024
However, implementing a dose-escalation strategy may enhance regorafenib's cost-effectiveness. Consequently, significant price reductions or optimizing the dose of regorafenib are required to achieve cost-effectiveness.
- | Prolia (denosumab) / Amgen
Retrospective data, Journal: Equivalence in osteoporosis workup and management after femoral neck fracture fixation and vertebral compression fracture cement augmentation: A single-center retrospective study highlighting persistent Underdiagnosis and Undertreatment. (Pubmed Central) - Jun 10, 2024
Consequently, significant price reductions or optimizing the dose of regorafenib are required to achieve cost-effectiveness. VCF patients, however, were more likely to receive denosumab and post-operative DEXA scans (p
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open, Post-transplantation: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. (clinicaltrials.gov) - Jun 10, 2024
P2, N=60, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
VCF patients, however, were more likely to receive denosumab and post-operative DEXA scans (p Not yet recruiting --> Recruiting
- ||| AMG 786 / Amgen
Trial completion, Trial completion date, Trial primary completion date: Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity (clinicaltrials.gov) - Jun 10, 2024
P1, N=65, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Aug 2023
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Reactivation after teprotumumab treatment for active thyroid eye disease. (Pubmed Central) - Jun 9, 2024
The proptosis and CAS regression occurs in the setting of disease reactivation in 80% of regressions. Teprotumumab treatment appears to offer minimal long-term improvement in diplopia.
- || Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. (Pubmed Central) - Jun 8, 2024
Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional chemotherapy in this setting...This review discusses novel approaches to integrating INO and/or blinatumomab into frontline ALL regimens, including the potential role of chemotherapy-free regimens in some subgroups. The role of MRD monitoring is also discussed, including how this can inform decisions for consolidative allogeneic HSCT or investigational approaches with CD19 CAR T-cells.
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Clinical, Journal: Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. (Pubmed Central) - Jun 8, 2024
P=N/A
The role of MRD monitoring is also discussed, including how this can inform decisions for consolidative allogeneic HSCT or investigational approaches with CD19 CAR T-cells. These findings provide evidence that migraine induction via the cGMP pathway can occur even under CGRP receptor blockade.
- | Fablyn (lasofoxifene) / Sermonix
Journal: Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. (Pubmed Central) - Jun 8, 2024
Lasofoxifene plus palbociclib also reduced bone metastases. These results suggest that lasofoxifene alone or combined with a CDK4/6 inhibitor may offer benefits to patients who have ER-low and HER2-positive, AI-resistant breast cancer, independent of ESR1 mutations.
- | Journal: Therapeutic Potential of Lipoprotein(a) Inhibitors. (Pubmed Central) - Jun 8, 2024
These agents are moving forward in clinical development, in order to determine whether Lp(a) lowering reduces cardiovascular risk. The results of these studies have the potential to transform our approach to the prevention of cardiovascular disease.
- | Camzyos (mavacamten) / BMS, omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. (Pubmed Central) - Jun 8, 2024
All-atom molecular dynamics simulations reveal how these molecules produce distinct effects in motor allostery thus impacting force production in opposite way. Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure. (Pubmed Central) - Jun 7, 2024
Preclinical and clinical trials have found that omecamtiv mecarbil improves cardiac contractility without increasing the risk of any of the harmful effects that are associated with the currently available inotropic agents. Omecamtiv mecarbil is a worthwhile advance and patients with systolic heart failure would benefit from pharmacological use of this drug.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Review, Journal: Cell cycle machinery in oncology: A comprehensive review of therapeutic targets. (Pubmed Central) - Jun 7, 2024
Future efforts should focus on combinatorial therapies, next-generation inhibitors, and biomarkers for patient selection. Targeting the cell cycle holds promise but further optimization is necessary to fully exploit it as an anti-cancer strategy across diverse malignancies.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Study on Cloning and Expression of TNF-? Variants in E. coli: Production, Purification, and Interaction with Anti-TNF-? Inhibitors. (Pubmed Central) - Jun 7, 2024
The high binding efficiency of sTNF-? with adalimumab, etanercept, and infliximab, evidenced in this study supports the feasibility of its use in therapeutic applications, contributing to more sustainable, cost-effective, and independent healthcare system.
- || Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Review, Journal, Metastases: Resistance to KRAS inhibition in advanced non-small cell lung cancer. (Pubmed Central) - Jun 7, 2024
Currently, there are only two approved targeted therapies (adagrasib and sotorasib) for advanced or metastatic KRAS-mutated NSCLC from the second-line setting onwards. In this narrative review, we will focus on KRAS, its molecular basis, the role of its co-mutations, clinical evidence for its inhibition, putative mutation to resistance, and future strategies to overcome resistance to KRAS inhibition.
- | Prolia (denosumab) / Amgen
Journal: Denosumab and metatarsal fracture healing: potential benefits with delayed remodeling: a case report. (Pubmed Central) - Jun 7, 2024
Denosumab may positively influence fracture healing in older adults with metatarsal fractures, potentially leading to delayed remodeling. However, further studies are needed to confirm these observations.